PMID- 26887289
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20181202
IS  - 1930-739X (Electronic)
IS  - 1930-7381 (Print)
IS  - 1930-7381 (Linking)
VI  - 24
IP  - 4
DP  - 2016 Apr
TI  - Adipose tissue natriuretic peptide receptor expression is related to insulin 
      sensitivity in obesity and diabetes.
PG  - 820-8
LID - 10.1002/oby.21418 [doi]
AB  - OBJECTIVE: Cardiac natriuretic peptides (NPs) bind to two receptors 
      (NPRA-mediator of signaling; NPRC-clearance receptor) whose ratio, NPRR 
      (NPRA/NPRC), determines the NP bioactivity. This study investigated the 
      relationship of NP receptor gene expression in adipose tissue and muscle with 
      obesity and glucose intolerance. Prospectively, the study also assessed whether 
      changes in NP receptor expression and thermogenic gene markers accompanied 
      improvements of insulin sensitivity. METHODS: A cross-sectional study of subjects 
      with a wide range of BMI and glucose tolerance (n = 50) was conducted, as well as 
      a randomized 12-week trial of subjects with type 2 diabetes mellitus (T2DM) 
      treated with pioglitazone (n = 9) or placebo (n = 10). RESULTS: NPRR mRNA was 
      significantly lower in adipose tissue of subjects with obesity when compared with 
      lean subjects (P </= 0.001). NPRR decreased with progression from normal glucose 
      tolerance to T2DM (P < 0.01) independently of obesity. Treatment of subjects with 
      T2DM with pioglitazone increased NPRR in adipose tissue (P </= 0.01) in conjunction 
      with improvements in insulin sensitivity and increases of the thermogenic markers 
      PPARgamma coactivator-1alpha and uncoupling protein 1 (P </= 0.01). CONCLUSIONS: Decreased 
      adipose tissue NPRR was associated with obesity, glucose intolerance, and insulin 
      resistance. This relationship was not observed for skeletal muscle NPRR. 
      Pharmacological improvement of insulin sensitivity in subjects with T2DM was tied 
      to improvement in NPRR and increased expression of genes involved in thermogenic 
      processes.
CI  - (c) 2016 The Authors Obesity published by Wiley Periodicals, Inc. on behalf of The 
      Obesity Society (TOS).
FAU - Kovacova, Zuzana
AU  - Kovacova Z
AD  - Translational Research Institute for Metabolism and Diabetes, Florida Hospital, 
      Orlando, Florida, USA.
FAU - Tharp, William G
AU  - Tharp WG
AD  - Division of Endocrinology, Diabetes and Metabolism, University of Vermont College 
      of Medicine, Burlington, Vermont, USA.
FAU - Liu, Dianxin
AU  - Liu D
AD  - Center for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery 
      Institute, Orlando, Florida, USA.
FAU - Wei, Wan
AU  - Wei W
AD  - Center for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery 
      Institute, Orlando, Florida, USA.
FAU - Xie, Hui
AU  - Xie H
AD  - Translational Research Institute for Metabolism and Diabetes, Florida Hospital, 
      Orlando, Florida, USA.
FAU - Collins, Sheila
AU  - Collins S
AD  - Center for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery 
      Institute, Orlando, Florida, USA.
FAU - Pratley, Richard E
AU  - Pratley RE
AD  - Translational Research Institute for Metabolism and Diabetes, Florida Hospital, 
      Orlando, Florida, USA.
AD  - Center for Metabolic Origins of Disease, Sanford Burnham Prebys Medical Discovery 
      Institute, Orlando, Florida, USA.
LA  - eng
SI  - ClinicalTrials.gov/NCT00656864
GR  - R01 DK103056/DK/NIDDK NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20160217
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiazolidinediones)
RN  - EC 4.6.1.2 (Receptors, Atrial Natriuretic Factor)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Adult
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/drug therapy/metabolism/physiopathology
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin Resistance/*physiology
MH  - Male
MH  - Middle Aged
MH  - *Obesity/metabolism/physiopathology
MH  - Pioglitazone
MH  - *Receptors, Atrial Natriuretic Factor/analysis/metabolism
MH  - Thiazolidinediones/therapeutic use
PMC - PMC5067565
OTO - NOTNLM
OT  - adipose tissue
OT  - natriuretic peptide receptors
OT  - obesity
OT  - type 2 diabetes mellitus
EDAT- 2016/02/19 06:00
MHDA- 2016/12/15 06:00
PMCR- 2016/10/18
CRDT- 2016/02/19 06:00
PHST- 2015/06/10 00:00 [received]
PHST- 2015/09/22 00:00 [revised]
PHST- 2015/10/30 00:00 [accepted]
PHST- 2016/02/19 06:00 [entrez]
PHST- 2016/02/19 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
PHST- 2016/10/18 00:00 [pmc-release]
AID - OBY21418 [pii]
AID - 10.1002/oby.21418 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2016 Apr;24(4):820-8. doi: 10.1002/oby.21418. Epub 2016 
      Feb 17.